NM_174936.4:c.993C>T

Variant summary

Our verdict is Benign. The variant received -18 ACMG points: 0P and 18B. BP4_StrongBP6_Very_StrongBP7BS1BS2_Supporting

The NM_174936.4(PCSK9):​c.993C>T​(p.Pro331Pro) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000294 in 1,457,672 control chromosomes in the GnomAD database, including 3 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★). Synonymous variant affecting the same amino acid position (i.e. P331P) has been classified as Likely benign.

Frequency

Genomes: 𝑓 0.00029 ( 1 hom., cov: 32)
Exomes 𝑓: 0.00029 ( 2 hom. )

Consequence

PCSK9
NM_174936.4 synonymous

Scores

2

Clinical Significance

Benign/Likely benign criteria provided, multiple submitters, no conflicts B:10

Conservation

PhyloP100: -3.07

Publications

2 publications found
Variant links:
Genes affected
PCSK9 (HGNC:20001): (proprotein convertase subtilisin/kexin type 9) This gene encodes a member of the subtilisin-like proprotein convertase family, which includes proteases that process protein and peptide precursors trafficking through regulated or constitutive branches of the secretory pathway. The encoded protein undergoes an autocatalytic processing event with its prosegment in the ER and is constitutively secreted as an inactive protease into the extracellular matrix and trans-Golgi network. It is expressed in liver, intestine and kidney tissues and escorts specific receptors for lysosomal degradation. It plays a role in cholesterol and fatty acid metabolism. Mutations in this gene have been associated with autosomal dominant familial hypercholesterolemia. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2014]
PCSK9 Gene-Disease associations (from GenCC):
  • hypercholesterolemia, autosomal dominant, 3
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: ClinGen, Genomics England PanelApp, Labcorp Genetics (formerly Invitae), Ambry Genetics
  • homozygous familial hypercholesterolemia
    Inheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -18 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.55).
BP6
Variant 1-55056186-C-T is Benign according to our data. Variant chr1-55056186-C-T is described in ClinVar as Benign/Likely_benign. ClinVar VariationId is 496568.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=-3.07 with no splicing effect.
BS1
Variant frequency is greater than expected in population eas. GnomAd4 allele frequency = 0.000287 (43/149774) while in subpopulation EAS AF = 0.00322 (16/4964). AF 95% confidence interval is 0.00202. There are 1 homozygotes in GnomAd4. There are 23 alleles in the male GnomAd4 subpopulation. Median coverage is 32. This position passed quality control check.
BS2
High Homozygotes in GnomAdExome4 at 2 AD,AR geneVariant has number of homozygotes lower than other variant known as pathogenic in the gene, so the strength is limited to Supporting.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
PCSK9NM_174936.4 linkc.993C>T p.Pro331Pro synonymous_variant Exon 6 of 12 ENST00000302118.5 NP_777596.2

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
PCSK9ENST00000302118.5 linkc.993C>T p.Pro331Pro synonymous_variant Exon 6 of 12 1 NM_174936.4 ENSP00000303208.5

Frequencies

GnomAD3 genomes
AF:
0.000287
AC:
43
AN:
149658
Hom.:
1
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0000248
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.000201
Gnomad ASJ
AF:
0.00144
Gnomad EAS
AF:
0.00322
Gnomad SAS
AF:
0.00147
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.000148
Gnomad OTH
AF:
0.000488
GnomAD2 exomes
AF:
0.000597
AC:
72
AN:
120672
AF XY:
0.000635
show subpopulations
Gnomad AFR exome
AF:
0.000140
Gnomad AMR exome
AF:
0.000158
Gnomad ASJ exome
AF:
0.00197
Gnomad EAS exome
AF:
0.00351
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.000203
Gnomad OTH exome
AF:
0.00133
GnomAD4 exome
AF:
0.000294
AC:
385
AN:
1307898
Hom.:
2
Cov.:
33
AF XY:
0.000297
AC XY:
189
AN XY:
636958
show subpopulations
African (AFR)
AF:
0.0000337
AC:
1
AN:
29716
American (AMR)
AF:
0.0000623
AC:
2
AN:
32110
Ashkenazi Jewish (ASJ)
AF:
0.00201
AC:
42
AN:
20924
East Asian (EAS)
AF:
0.00464
AC:
157
AN:
33824
South Asian (SAS)
AF:
0.000610
AC:
40
AN:
65592
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
44340
Middle Eastern (MID)
AF:
0.000505
AC:
2
AN:
3962
European-Non Finnish (NFE)
AF:
0.000103
AC:
105
AN:
1024238
Other (OTH)
AF:
0.000677
AC:
36
AN:
53192
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.473
Heterozygous variant carriers
0
19
39
58
78
97
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
10
20
30
40
50
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.000287
AC:
43
AN:
149774
Hom.:
1
Cov.:
32
AF XY:
0.000315
AC XY:
23
AN XY:
73032
show subpopulations
African (AFR)
AF:
0.0000247
AC:
1
AN:
40486
American (AMR)
AF:
0.000201
AC:
3
AN:
14954
Ashkenazi Jewish (ASJ)
AF:
0.00144
AC:
5
AN:
3468
East Asian (EAS)
AF:
0.00322
AC:
16
AN:
4964
South Asian (SAS)
AF:
0.00147
AC:
7
AN:
4754
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10196
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
286
European-Non Finnish (NFE)
AF:
0.000148
AC:
10
AN:
67684
Other (OTH)
AF:
0.000483
AC:
1
AN:
2072
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.484
Heterozygous variant carriers
0
2
3
5
6
8
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.000619
Hom.:
1
Bravo
AF:
0.000404

ClinVar

Significance: Benign/Likely benign
Submissions summary: Benign:10
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Benign:5
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Dec 01, 2023
CeGaT Center for Human Genetics Tuebingen
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

PCSK9: BP4, BP7, BS1 -

Aug 07, 2019
Quest Diagnostics Nichols Institute San Juan Capistrano
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Jun 09, 2016
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Variant summary: The PCSK9 c.993C>T (p.Pro331Pro) variant causes a synonymous change involving a non-conserved nucleotide with 5/5 splice prediction tools predicting no significant impact on splicing, although these predictions have yet to be functionally assessed. The variant of interest was observed in the large, broad control population, ExAC, with an allele frequency of 27/22050 (1/816), predominantly in the Asian cohort, 19/4192 (1/222), which significantly exceeds the estimated maximal expected allele frequency for a pathogenic PCSK9 variant of 1/53191 (0.0000188), suggesting this variant is a common polymorphism found in population(s) of Asian origin. The variant of interest has been reported in affected individuals via publications and classified as a common polymorphism. Therefore, the variant of interest has been classified as Benign. -

May 12, 2021
GeneDx
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is associated with the following publications: (PMID: 14727156, 18718593) -

not specified Benign:1
Apr 09, 2025
Molecular Diagnostic Laboratory for Inherited Cardiovascular Disease, Montreal Heart Institute
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Hypercholesterolemia, autosomal dominant, 3 Benign:1
Dec 25, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Hypercholesterolemia, familial, 1 Benign:1
Jan 02, 2018
Robarts Research Institute, Western University
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Cardiovascular phenotype Benign:1
Dec 15, 2017
Ambry Genetics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Familial hypercholesterolemia Benign:1
Dec 03, 2017
Color Diagnostics, LLC DBA Color Health
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.55
CADD
Benign
7.0
DANN
Benign
0.87
PhyloP100
-3.1
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.7
Mutation Taster
=100/0
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs376753957; hg19: chr1-55521859; API